桂枝茯苓方治疗子宫肌瘤的疗效及对基质金属蛋白酶2、核因子-κBp65表达水平的影响
|
摘要
目的:分析桂枝茯苓方治疗子宫肌瘤的疗效及基质金属蛋白酶2(MMP-2)、核因子-κB p65表达水平的影响。方法:选取子宫肌瘤患者86例,根据治疗方法不同分为对照组和观察组。对照组患者采用常规对症治疗,观察组患者采用常规对症治疗联合桂枝茯苓方治疗,分析两组患者治疗后的临床效果。结果:观察组患者总有效率为90.70%,对照组为72.09%,观察组患者总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者MMP-2、NF-κB p65、EGF、Bcl-2、Ang-2水平比较,差异无统计学意义(P>0.05)。治疗后,观察组患者MMP-2、NF-κB p65、EGF、Bcl-2、Ang-2水平低于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后月经量多、小腹凉、腰酸、经前乳胀例数低于对照组,但血块的例数与对照组比较,差异有统计学意义(P<0.05)。结论:桂枝茯苓方治疗子宫肌瘤的疗效显著,可降低患者血清MMP-2、NF-κBp65、Bcl-2的表达水平,改善经期症状。
Objective:To analyze the therapeutic effect of Guizhi Fuling Recipe on uterine leiomyoma and the effect on expressions of matrix metalloproteinase-2(MMP-2) and nuclear factor-κB p65. Methods:Eighty-six cases of hysteromyoma were selected and divided into control group and observation group according to different treatment methods. The patients in the control group were treated with conventional symptomatic therapy and the patients in the observation group were treated with the combination of Guizhi Fuling Recipe. The clinical effects of the two groups were analyzed. Results:The total effective rate was 90.70% in the observation group and 72.09% in the control group. The total effective rate in the observation group was higher than that in the control group(P<0.05). Before treatment, the levels of MMP-2, NF-κB p65 and EGF-2 Ang-2 were not significantly different between the two groups(P>0.05). After treatment, the levels of MMP-2,NF-κB p65,EGF,Bcl-2 and Ang-2 in the observation group were lower than those in the control group(P<0.05). The observation group's cases of lower menstrual volume,abdominal cooling, lumbar acid and premammary distention after treatment were lower than that of the control group, but the number of blood clots was significantly lower than that of the control group(P<0.05). Conclusion:Guizhi Fuling Recipe has a significant therapeutic effect on uterine leiomyoma, which can reduce the expressions of MMP-2, NF-κ Bp65 and Bcl-2 and improve menstrual symptoms.
Objective:To analyze the therapeutic effect of Guizhi Fuling Recipe on uterine leiomyoma and the effect on expressions of matrix metalloproteinase-2(MMP-2) and nuclear factor-κB p65. Methods:Eighty-six cases of hysteromyoma were selected and divided into control group and observation group according to different treatment methods. The patients in the control group were treated with conventional symptomatic therapy and the patients in the observation group were treated with the combination of Guizhi Fuling Recipe. The clinical effects of the two groups were analyzed. Results:The total effective rate was 90.70% in the observation group and 72.09% in the control group. The total effective rate in the observation group was higher than that in the control group(P<0.05). Before treatment, the levels of MMP-2, NF-κB p65 and EGF-2 Ang-2 were not significantly different between the two groups(P>0.05). After treatment, the levels of MMP-2,NF-κB p65,EGF,Bcl-2 and Ang-2 in the observation group were lower than those in the control group(P<0.05). The observation group's cases of lower menstrual volume,abdominal cooling, lumbar acid and premammary distention after treatment were lower than that of the control group, but the number of blood clots was significantly lower than that of the control group(P<0.05). Conclusion:Guizhi Fuling Recipe has a significant therapeutic effect on uterine leiomyoma, which can reduce the expressions of MMP-2, NF-κ Bp65 and Bcl-2 and improve menstrual symptoms.
引文
[1] 叶明珠,邓新粮,薛敏.围绝经期子宫肌瘤的处理[J].中国实用妇科与产科杂志,2016,32(2):126-131.
[2] Jeong JH,Hong KP,Kim YR,et al.Usefulness of modified BRB technique in treatment to ablate uterine fibroids with magnetic resonance image-guided high-intensity focused ultrasound[J].Obstet Gynecol Sci,2017,60(1):92-99.
[3] 张翠菊.双橘颗粒联合亮丙瑞林治疗子宫肌瘤的临床研究[J].现代药物与临床,2017,32(5):840-843.
[4] 张伟凤.桂枝茯苓胶囊联合米非司酮治疗子宫肌瘤[J].吉林中医药,2016,36(2):154-157.
[5] 谢幸,苟文丽.妇产科学[M].北京:人民卫生出版社,2013:336.
[6] 郑筱萸.中药新药临床研究指导原则(试行)[S].中国医药科技出版社,2002:156.
[7] Patel A,Malik M,Britten J,et al.Mifepristone inhibits extracellular matrix formation in uterine leiomyoma[J].Fertil Steril,2016,105(4):1102-1110.
[8] Marciniak A,Szydkowska I,Brodowska A,et al.New methods of uterine fibroids treatment[J].Pol Merkur Lekarski,2016,41(246):303-305.
[9] 方海娅,张海燕,寿华锋.米非司酮治疗围绝经期子宫肌瘤的临床研究[J].中国临床药理学杂志,2016,32(11):987-989.
[10] 王美英.肌瘤内消方联合高强度聚焦超声治疗子宫肌瘤疗效观察[J].现代中西医结合杂志,2016,25(5):541-543.
[11] 王越,李霞.少腹逐瘀汤治疗40例子宫肌瘤的临床疗效观察[J].中医药信息,2016,33(1):90-92.
[12] 黄菊,曾新,王荣跃.米非司酮单用及与宫瘤消胶囊联用治疗子宫肌瘤的临床效果[J].中国肿瘤临床与康复,2016,23(2):206-208.
[13] 梁旭.四君子汤合桂枝茯苓丸加减治疗子宫肌瘤临床研究[J].亚太传统医药,2016,6(13):145-146.
[14] Kapur A,Angomchanu R,Dey M.Efficacy of use of long-term,low-dose mifepristone for the treatment of fibroids[J].J Obstet Gynaecol India,2016,66(Suppl 1):494-498.
[15] Salem WG,Bitar R,Zreik T,et al.Intra-peritoneal leiomyoma of the round ligament in a patient with Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome[J].Facts Views Vis Obgyn,2016,8(4):233-235.
[16] 王伟强,侯小霞,刘晨,等.丹鳖胶囊联合米非司酮治疗子宫肌瘤的疗效评价及对Bcl-2、Bax、FSH、E2水平的影响[J].现代生物医学进展,2017,17(34):6697-6700,6734.
[17] Abbas MG,Saeedeh S,Farshid K,et al.Association of FAS A-670G polymorphism and risk of uterine leiomyoma in a southeast iranian population[J].Rep Biochem Mol Biol,2016,5(1):51-55.
[18] Murai S,Matuszkiewicz J,Okuzono Y,et al.Aurora B inhibitor TAK-901 synergizes with BCL-xL inhibition by inducing active BAX in cancer cells[J].Anticancer Res,2017,37(2):437-444.
[19] Marsh EE,Chibber S,Wu J,et al.Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 expression and regulation in uterine leiomyoma[J].Fertil Steril,2016,105(4):1070-1075.
[20] 王桂彩.子宫肌瘤患者应用中医活血化瘀方治疗疗效及安全性探讨[J].辽宁中医药大学学报,2016,3(13):183-185.
[21] 韩兆忠,刘茜,郑伟然,等.桂枝茯苓胶囊联合米非司酮治疗子宫肌瘤临床疗效和安全性的系统性评价[J].世界科学技术-中医药现代化,2016,18(3):543-551.
[2] Jeong JH,Hong KP,Kim YR,et al.Usefulness of modified BRB technique in treatment to ablate uterine fibroids with magnetic resonance image-guided high-intensity focused ultrasound[J].Obstet Gynecol Sci,2017,60(1):92-99.
[3] 张翠菊.双橘颗粒联合亮丙瑞林治疗子宫肌瘤的临床研究[J].现代药物与临床,2017,32(5):840-843.
[4] 张伟凤.桂枝茯苓胶囊联合米非司酮治疗子宫肌瘤[J].吉林中医药,2016,36(2):154-157.
[5] 谢幸,苟文丽.妇产科学[M].北京:人民卫生出版社,2013:336.
[6] 郑筱萸.中药新药临床研究指导原则(试行)[S].中国医药科技出版社,2002:156.
[7] Patel A,Malik M,Britten J,et al.Mifepristone inhibits extracellular matrix formation in uterine leiomyoma[J].Fertil Steril,2016,105(4):1102-1110.
[8] Marciniak A,Szydkowska I,Brodowska A,et al.New methods of uterine fibroids treatment[J].Pol Merkur Lekarski,2016,41(246):303-305.
[9] 方海娅,张海燕,寿华锋.米非司酮治疗围绝经期子宫肌瘤的临床研究[J].中国临床药理学杂志,2016,32(11):987-989.
[10] 王美英.肌瘤内消方联合高强度聚焦超声治疗子宫肌瘤疗效观察[J].现代中西医结合杂志,2016,25(5):541-543.
[11] 王越,李霞.少腹逐瘀汤治疗40例子宫肌瘤的临床疗效观察[J].中医药信息,2016,33(1):90-92.
[12] 黄菊,曾新,王荣跃.米非司酮单用及与宫瘤消胶囊联用治疗子宫肌瘤的临床效果[J].中国肿瘤临床与康复,2016,23(2):206-208.
[13] 梁旭.四君子汤合桂枝茯苓丸加减治疗子宫肌瘤临床研究[J].亚太传统医药,2016,6(13):145-146.
[14] Kapur A,Angomchanu R,Dey M.Efficacy of use of long-term,low-dose mifepristone for the treatment of fibroids[J].J Obstet Gynaecol India,2016,66(Suppl 1):494-498.
[15] Salem WG,Bitar R,Zreik T,et al.Intra-peritoneal leiomyoma of the round ligament in a patient with Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome[J].Facts Views Vis Obgyn,2016,8(4):233-235.
[16] 王伟强,侯小霞,刘晨,等.丹鳖胶囊联合米非司酮治疗子宫肌瘤的疗效评价及对Bcl-2、Bax、FSH、E2水平的影响[J].现代生物医学进展,2017,17(34):6697-6700,6734.
[17] Abbas MG,Saeedeh S,Farshid K,et al.Association of FAS A-670G polymorphism and risk of uterine leiomyoma in a southeast iranian population[J].Rep Biochem Mol Biol,2016,5(1):51-55.
[18] Murai S,Matuszkiewicz J,Okuzono Y,et al.Aurora B inhibitor TAK-901 synergizes with BCL-xL inhibition by inducing active BAX in cancer cells[J].Anticancer Res,2017,37(2):437-444.
[19] Marsh EE,Chibber S,Wu J,et al.Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 expression and regulation in uterine leiomyoma[J].Fertil Steril,2016,105(4):1070-1075.
[20] 王桂彩.子宫肌瘤患者应用中医活血化瘀方治疗疗效及安全性探讨[J].辽宁中医药大学学报,2016,3(13):183-185.
[21] 韩兆忠,刘茜,郑伟然,等.桂枝茯苓胶囊联合米非司酮治疗子宫肌瘤临床疗效和安全性的系统性评价[J].世界科学技术-中医药现代化,2016,18(3):543-551.